Featured Editorial

  1. Is Blockchain The Solution To Derisking Unreliable Clinical Trial Data? 8/16/2024

    Technological advances have provided fertile ground for scientific fraud, but blockchain just may be the key to ensuring a transparent, trusted, and certified process for collecting, managing, and analyzing clinical trial data.

  2. A Quick & Easy Guide To Site-Facing Clinical Trial Technologies 8/15/2024

    Consultant Aurea Flores, Ph.D. summarizes some of the clinical trial technologies used by clinical research sites, their capabilities, and how sponsors and sites might best evaluate their use in clinical research.

  3. What Sites Need: Trial Technology Integration, Support, And Evaluation 8/14/2024

    In part two of this series, SCRS Vice President of Site Engagement Jimmy Bechtel discusses how site technology should be chosen, customized, and eventually evaluated for success.

  4. Some Truths You Can't Avoid About eCOA 8/13/2024

    The advantages of eCOA systems often overshadow some of the potential challenges they could create. Robert Goldman expounds on some of his first-hand experiences over the years with ePRO and eCOA implementations that went awry.

  5. What Sites Need: Trial Technology Selection, Buy-In, And Implementation 8/13/2024

    SCRS Vice President of Site Engagement Jimmy Bechtel poses questions and offers helpful tips aimed at helping sponsors understand site technology needs in this two-part series, with part one focused on technology selection and implementation.

  6. Managing Risk In New And Emerging Trial Technology Trends 7/31/2024

    As technology advances, the risk that comes with integrating them into clinical trials rises. Beazley U.S. Life Sciences Underwriter Brendan Tarte discusses how to manage risk with tech like wearables, DHTs, AI/ML, and more.

  7. Correct But Misleading: AI Hallucinations In Complex Decision-Making 7/11/2024

    Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical expectations. Regulators are mandating transparency in AI models used for drug testing and development.

  8. Could GenAI Dramatically Reduce The Cost Of Regulatory Medical Writing? 7/3/2024

    Time-poor regulatory professionals stand to benefit substantially from generative AI, which can speed up the creation of marketing authorization applications or life cycle maintenance activities, for example. However, success will depend on how the technology is applied and controlled.

  9. Takeda Chooses Wearable To Improve Patient Experience & Data In Sleep Study 6/27/2024

    Takeda Head of the Orexin Franchise Development and Neuroscience Portfolio Strategy Elena Koundourakis explains why her team decided to pursue the use of DHTs and the benefits of doing so, for both the patients and the data accuracy. 

  10. What Drives eConsent Adoption? Reasons May Be Different Than You Think 6/13/2024

    Increasing efficiency and reducing cost are significant drivers for adopting eConsent platforms. But are they really the factors holding back widespread adoption? Gatewood Global Principal Jeanie Magdalena Gatewood reveals other drivers in her independent research.